Alzheimer’s drug Leqembi expected to generate $12.9bn in sales by 2028
Pharmafile
MARCH 30, 2023
After receiving FDA approval in January 2023, Biogen/Eisai’s new Alzheimer’s disease Leqembi is expected to become a blockbuster, with a predicted $12.9bn predicted to be made in sales between 2023 and 2028. read more
Let's personalize your content